Gene-Guided Immunotherapy Misses Mark in Recurrent/Metastatic Head and Neck Cancer
(MedPage Today) -- Gene-guided treatment selection for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) failed to improve disease control versus random treatment selection in a small preliminary clinical trial.
Personalized treatment...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Genetics | Head and Neck Cancer | Hematology | HNSCC | Immunotherapy | Skin Cancer | Squamous Cell Carcinoma